Symbiotec Pharmalab

** Shares of India's Symbiotec Pharmalab SYMI.NS rise 3.4% to 1,217.20 rupees

** Stock on track for fourth straight session of gains

** Symbiotec's unit Knovea Pharmaceutical enters into strategic commercialization agreement with global pharmaceutical company

** Says cannot disclose name of global pharmaceutical company due to "confidentiality obligations"
** SYMI says partner will commercialise and distribute two dual vial chamber-based injectable products in the US

** Co says partnership opens commercial pathway in world's largest pharmaceutical market

(Reporting by Anushka Rajvedi in Bengaluru)

((mailto: [email protected]))

Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, signed a definitive agreement granting an unnamed leading global pharmaceutical company exclusive rights to commercialise and distribute two dual-chamber vial injectable products in the United States. Under the arrangement, Knovea retained development, regulatory submissions, manufacturing and supply, while the partner took on US commercialisation and distribution, with milestone payments through development, approval and launch alongside profit-sharing after launch. The two products addressed a US market estimated at about US$288 million, where the innovator was the sole supplier with a dual-chamber presentation. Knovea filed its first dual-chamber vial abbreviated new drug application in September as a first generic. The Mhow facility housing the dual-chamber platform was commissioned with capacity of 18-20 million vials. Symbiotec reported revenue of Rs869.1 crore in the year to March, with exports accounting for 67% of sales across more than 200 customers in over 40 countries.

Powered by Tijori

Sept 30 (Reuters) - Symbiotec Pharmalab Limited SYMI.NS:

• SYMBIOTEC PHARMALAB - UNIT ENTERS INTO STRATEGIC COMMERCIALIZATION AGREEMENT

• SYMBIOTEC PHARMALAB - AGREEMENT GRANTS EXCLUSIVE RIGHTS TO DISTRIBUTE TWO DCV INJECTABLE PRODUCTS IN U.S.

Source text: ID:nNSE5M0nh2

Further company coverage: SYMI.NS

(([email protected];))

Sept 29 (Reuters) - Symbiotec Pharmalab Limited SYMI.NS:

• RECEIVES USFDA EIR FOR PITHAMPUR FACILITY WITH VAI STATUS

Further company coverage: SYMI.NS

(([email protected];))

** Shares of Symbiotec Pharmalab SYMI.NS down 3.11% at 1,120.10 rupees after reporting first results since IPO

** Stock could snap three consecutive sessions of gains

** Co reports 53% decline in quarterly net profit to 141.56 million rupees ($1.48 million)

** Reports Q1 revenue from operations of 2.18 billion rupees vs 2.03 billion rupees in the year-ago period

** The drag on EBITDA was mainly due to expenses from new businesses which are yet to generate significant traction--analysts at ICICI Direct Research

** Shares up 13.4% since trading debut on September 1

($1 = 95.8100 Indian rupees)

(Reporting by Saikeerthi in Bengaluru)

(([email protected]; (+91) 8296756080))

Symbiotec Pharmalab recreated pledges over 8.24 million promoter-group shares, equal to 12.82% of its share capital, in favour of Beacon Trusteeship, the security trustee for debentures. The pledges dated September 8 to 10 followed a temporary release used to create the IPO lock-in, and the process left the pledged holding effectively unchanged. Symbiotec completed a ₹1,757 crore IPO comprising a ₹150 crore fresh issue and a ₹1,607 crore offer for sale. Revenue reached ₹869.1 crore in FY26, while EBITDA was ₹232 crore and net debt was ₹380.9 crore.

Powered by Tijori

Beacon Trusteeship disclosed that 34,93,464 Symbiotec Pharmalab shares, representing 5.44% of voting capital and 5.43% on a fully diluted basis, had been pledged in its favour as debenture trustee for non-convertible debentures issued by Satwani Holdings (India) Private Limited. The pledges were created by Anil Satwani, Sushil Satwani, Kashish Satwani and Satwani Holdings LLP on 8 and 9 September 2026. The security formed part of a debenture trust deed dated 10 December 2025, amended on 18 December, and included a covenant requiring repayment if the promoter group ceased to own at least 26% of the target's fully diluted share capital free of encumbrance. Symbiotec had reported FY26 revenue from operations of ₹869.1 crore and net debt of ₹380.9 crore at year-end.

Powered by Tijori

Mirae Asset Mutual Fund acquired 3,497,420 shares of Symbiotec Pharmalab in the open market on September 1, raising its holding from 0.78% to 6.22%. The fund’s stake rose from 498,019 shares to 3,995,439 shares, while Symbiotec’s total voting capital remained at 64,256,112 shares. Symbiotec’s August red-herring prospectus set out a ₹1,757 crore IPO, comprising ₹150 crore of fresh issue and ₹1,607 crore offered by selling shareholders. The API and intermediates maker reported FY26 revenue of ₹869.1 crore, EBITDA of ₹232 crore and net debt of ₹380.9 crore.

Powered by Tijori

** Shares of India's Symbiotec Pharmalab SYMI.NS rise 18.8% to 1,174 rupees in trading debut, after listing at IPO issue price of 988 rupees

** Co valued at 73.89 billion rupees ($778.98 million)

** Drugmaker's 17.57-billion-rupee IPO comprised fresh issue of shares worth up to 1.50 billion rupees and offer for sale of shares worth up to 16.07 billion rupees

** IPO was subscribed 71.26 times, led by institutional buyers, who bid 172 times the shares set aside for them

** Trading volume at 22.41 million shares

($1 = 94.8550 Indian rupees)

(Reporting by Payel Das in Bengaluru)

(([email protected]))